STOCK TITAN

Coherus Biosciences Inc - CHRS STOCK NEWS

Welcome to our dedicated news page for Coherus Biosciences (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coherus Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coherus Biosciences's position in the market.

Rhea-AI Summary
Coherus BioSciences, Inc. granted options to purchase 170,000 shares of common stock to newly hired employees. The options have an exercise price of $2.59 per share, based on the closing trading price on the grant date. The grants were made under the 2016 Employment Commencement Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences, Inc. launches UDENYCA ONBODY, an innovative on-body injector for pegfilgrastim-cbqv, with a five-minute delivery time and a retractable needle mechanism for cancer patients. Positive feedback from providers and patients indicates growing demand for UDENYCA, offering a convenient and safe treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences, Inc. has revised its loan agreement with Pharmakon Advisors, LP, reducing the principal balance to $75 million upon a projected paydown of $175 million in Q2 2024. The revenue covenant has also been reduced to $125 million, and the term loan annual interest expense is expected to be reduced by approximately 70%. This agreement follows the divestiture of the ophthalmology franchise to Sandoz, and the company aims to lower its projected annual interest payments significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
Rhea-AI Summary
Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced the divestiture of its CIMERLI ophthalmology franchise to Sandoz for $170 million in upfront, all-cash consideration. The transaction aims to allow Coherus to focus on its core therapeutic area, oncology, by reducing debt, interest costs, and overhead costs. The company's oncology assets include the UDENYCA franchise, LOQTORZI, and an immuno-oncology pipeline of next-generation tumor microenvironment oncology drug candidates. The closing is anticipated in the first half of 2024, subject to certain closing conditions and approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences, Inc. presents promising data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug in combination with atezolizumab and bevacizumab for the treatment of liver cancer. The data demonstrates a 38% objective response rate, including three complete responses, and supports continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
clinical trial
-
Rhea-AI Summary
INOVIO (INO) and Coherus BioSciences (CHRS) to evaluate combination therapy in Phase 3 trial for patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
Rhea-AI Summary
INOVIO (INO) and Coherus BioSciences (CHRS) to evaluate combination therapy in Phase 3 trial for patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
conferences
-
Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) launches LOQTORZI, the first and only FDA-approved treatment for NPC in all lines of therapy. LOQTORZI is indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status. The drug is now available for purchase through select specialty distributors in the United States. LOQTORZI has demonstrated impressive clinical benefits, including progression-free survival (PFS) and overall survival (OS), offering new hope for extended survival to patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced FDA approval of UDENYCA ONBODY, an on-body injector for pegfilgrastim, with a unique retractable needle mechanism and five-minute delivery time. The device is designed to maximize safety and comfort for cancer patients receiving pegfilgrastim, offering a novel administration option for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.39%
Tags
fda approval
Coherus Biosciences Inc

Nasdaq:CHRS

CHRS Rankings

CHRS Stock Data

278.41M
102.55M
1.33%
79.08%
25.26%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About CHRS

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp